Synairgen raises £87m to bring Covid-19 treatment to market
UK biotech firm Synairgen has finished the second leg of an £87m capital increase to fund the next round of clinical trials of a treatment designed to alleviate the respiratory symptoms of Covid-19.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts